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Abstract: Stroke is the second cause of death worldwide and one of the leading causes of disability. Approximately 25% 
of strokes are recurrent.  
In patients who are at high risk because they already have occlusive vascular disease, long-term antiplatelet therapy (eg, 
with aspirin) reduces the yearly risk of serious vascular events (non-fatal myocardial infarction, non-fatal stroke, or vascu-
lar death) by about a quarter. Current recommendations for prevention of secondary stroke indicate for the broad use of 
antiplatelet therapy for the prevention of recurrent stroke in patients with a history of non-cardioembolic stroke or TIA. 
For primary prevention, however, the balance is less clear because the risks without aspirin, and hence the absolute benefi 
ts of aspirin, are generally an order of magnitude lower than in secondary prevention. 
In patients who are at high risk because they already have occlusive vascular disease, long-term antiplatelet therapy (e.g. 
with aspirin) reduces the yearly risk of serious vascular events (non-fatal myocardial infarction, non-fatal stroke, or vascu-
lar death) by about a quarter. 
Although several trials have investigated the use of antiplatelet drugs in ischemic stroke patients, ascertaining the sure 
benefit, especially in secondary prevention in non-cardioembolic stroke, various issues remains unclarified, and new ques-
tions arise with the analysis of the results of available trials. 
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INTRODUCTION  
 Stroke is one of the main causes of death and disability 
worldwide [1]. Antithrombotic therapy is actually a corner-
stone for the therapy of both acute and chronic cerebrovascu-
lar disease, having showed a clear effectiveness either in 
acute stroke treatment and in prevention of new cerebrovas-
cular events. Antiplatelet agents are a heterogenous class of 
drugs that have been successfully used for more than 2 dec-
ades in secondary stroke prevention. These agents include 
aspirin, (an irreversible inhibitor of cyclooxygenase-1, which 
in turn inhibits the formation of tromboxane A2) with or 
without dipyridamole (whose mechanism of action is domi-
nated by inhibition of platelet phosphodiesterase E5 through 
increasing of cyclic AMP), and more recently, the thieno-
pyridine ticlopidine and clopidogrel (a P2Y12 adenosine 
diphosphate receptor blocker). Platelets play a pivotal role in 
the development and progression of brain ischemia. An asso-
ciation was observed between the extent and duration of 
platelet activation and stroke severity [2]. Antithrombotics 
prevent the formation of blood clots that can become lodged 
in a cerebral artery and cause strokes. Antiplatelet drugs pre-
vent clotting by decreasing the activity of platelets, blood  
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cells that contribute to the clotting property of blood. These 
drugs reduce the risk of blood-clot formation, thus reducing 
the risk of ischemic stroke. The biological activity of anti-
platelet drugs goes widely beyond the reduction of platelet 
activity including effects both locally on other blood ele-
ments and within the vessel wall as well as more remote ef-
fects on other cell types throughout the body. Antiplatelet 
drugs provide significant effects in tissues damages by cere-
bral ischaemia: may prevent distal and proximal propagation 
of arterial thrombus, prevent re-embolization, prevent plate-
let aggregation in the microcirculation, reduce the release of 
thromboxane and other neurotoxic eicosanoids. All these 
effects in the acute phase guarantee a reduction of acute 
stroke severity, through reduction of neuronal damage, and 
therefore, a more favourable outcome.  
 The importance of antiplatelet agents for both the preven-
tion and treatment of ischemic disease was a concept devel-
oped as the consequence of some research that showed: (a) 
the contribution of platelets to both cardiac [3] and carotid 
disease; (b) development of reproducible assays to quantify 
platelet activation [4]. 
 Most strokes are caused by a sudden blockage of an ar-
tery in the brain (called an ischaemic stroke) that is usually 
due to a blood clot. Treatment with antiplatelet drugs such as 
aspirin may prevent clots from forming preventing ischemic 
event and, during the acute phase of stroke, reducing forma-
tion of new clots, hence improve recovery. However anti-
platelet drugs may also cause bleeding in the brain which 
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could offset any benefits. Several studies have evaluated the 
role of one antiplatelet agent, aspirin, in reducing stroke se-
verity [5-7]. Mechanisms by which antiplatelet agents may 
reduce stroke severity include stabilization of plaque and 
decreasing platelet aggregation thereby reducing size and 
frequency of thromboembolic emboli [8]. Furthermore, it is 
thought that antiplatelet agents such as aspirin may confer 
additional benefit on stroke severity beyond their presumed 
primary mechanism of action through anti-inflammatory and 
neuroprotective mechanisms [9]. 
 Aim of this review is to summarize the main available 
evidence regarding the use of antiplatelet drugs in both pri-
mary and secondary prevention of ischemic stroke. 
ANTIPLATELET DRUGS FOR PRIMARY PREVEN-
TION OF ISCHEMIC STROKE 
 The strategy of prevention of the first ischemic cerebral 
event represent a decisive approach in order to reduce mor-
bility and mortality related to cerebrovascular disease. We 
have consistent evidence that a global intervention aimed to 
reduce the burder of risk of the patient is a winning approach 
for reducing cereborvascular risk. So, tight control of hard 
risk factor such as hypertension or the prevention or reduc-
tion of other target-organ damage, including congestive heart 
failure and renal failure are of great effectiveness [10]. 
 Overall, antihypertensive therapy is associated with a 
35% to 44% reduction in the incidence of stroke [11]. Like-
wise, statin therapy has been shown to produce consistent 
benefits in large randomized trials in decreasing stroke risk 
[12]. The risk of stroke in diabetic patients with hypertension 
is increased and blood pressure and blood glucose levels 
should be controlled. Atrial fibrillation alone is associated 
with a 3- to 4-fold increased risk of stroke after adjustment 
for other vascular risk factors [13].  
 Over the control of cerebrovascular risk factor, effective-
ness of treatment with antiplatelet drugs of relatively healthy 
but high-risk subjects, in order to prevent the first ischemic 
event was tested in several trials.  
ASPIRIN 
 Aspirin is surely the most widely studied antiplatelet 
drug, and is considered affordable, broadly available, and 
reasonably safe. Data collected in three decades of trials at-
tributed to aspirin a potential combined risk reduction of 
stroke, myocardial infarction and vascular death by a 23 % 
[14]. Clinical benefits over placebo have been shown for 
doses from 50 mg to 1.3 g, but the risk of upper gastrointes-
tinal events (ulcers or bleeding) increases with the dose, so 
that some recommendations insist that ‘doses greater than 80 
mg should not be routinely prescribed, whereas a larger 
spectrum (50–325 mg) is accepted in other recommendations  
 Although aspirin increases the risk of major bleeding by 
about 70% (risk ratio [RR] 1·71 [95% CI 1·41–2·08]), the 
absolute annual increase is modest (0·13% [0·08–0·20%]), 
indicating that one additional major bleeding episode will 
occur each year for every 769 patients (95% CI 500–1250) 
treated with aspirin [15, 16]. 
 The Physicians’ Health Study [17], was a randomized, 
double blind, placebo-controlled trial designed to determine 
whether low-dose aspirin (325 mg every other day) de-
creased cardiovascular mortality. Among 22,071 participants 
with a mean follow-up of 60.2 months, although a 44 % 
RRR of myocardial infarction, there was a slighty unsignifi-
cant increase of risk of stroke, mainly due to hemorrhagic 
stroke. As a result, this study did not advocate for aspirin as 
a primary preventive strategy for stroke.  
 The Women’s Health Study [18], randomized 39,876 
initially asymptomatic women aged 45 years of age and 
older to receive 100 mg of aspirin or placebo on alternate 
days. Patients were followed for 10 years, with the primary 
endpoint being a first major vascular event (non-fatal MI, 
non-fatal stroke, or cardiovascular death). Unlike data from 
prior studies that included mainly men, this study found a 
non-significant 9% reduction (Relative Risk (RR) = 0.91; 
95% Confidence Interval (CI) 0.80 to 1.03; P = 0 .13) in the 
combined primary end point among women, but a statisti-
cally significant 17% reduction in the risk of stroke (RR = 
0.83; 95% CI 0.69 to 0.99; P= 0.04). This was based on a 
24% reduction in the risk of ischemic stroke and a non-
significant increase in the risk of hemorrhagic stroke. The 
most consistent benefit for aspirin was in women  65 years 
of age at study entry.  
 Recently, a new Antithrombotic Trialists (ATT) meta-
analyses [19] evaluated incidence of serious vascular events 
(myocardial infarction, stroke, or vascular death) and major 
bleedings in six primary prevention trials (95,000 individuals 
at low average risk, 660,000 person-years, 3554 serious vas-
cular events) and 16 secondary prevention trials (17,000 in-
dividuals at high average risk, 43,000 person-years, 3306 
serious vascular events) that compared long-term aspirin vs. 
control. In the primary prevention trials, aspirin allocation 
yielded a 12% proportional reduction in serious vascular 
events (0.51% aspirin vs. 0.57% control per year, p=0.0001), 
due mainly to a reduction of about a fifth in non-fatal myo-
cardial infarction (0.18% vs. 0.23% per year, p<0.0001). The 
net effect on stroke was not significant (0.20% vs. 0.21% per 
year, p=0.4: haemorrhagic stroke 0.04% vs. 0.03%, p=0.05; 
other stroke 0.16% vs. 0.18% per year, p=0.08). Vascular 
mortality did not differ significantly (0.19% vs. 0.19% per 
year, p=0.7). Aspirin allocation increased major gastrointes-
tinal and extracranial bleeds (0.10% vs. 0.07% per year, 
p<0.0001), and the main risk factors for coronary disease 
were also risk factors for bleeding. The data collected re-
garding the aggregate of all serious vascular events seemed 
similar for men and women. On the basis of this new ATT 
metanalysis authors conclude that in primary prevention 
without previous disease, aspirin is of uncertain net value as 
the reduction in occlusive events needs to be weighed against 
any increase in major bleeds. Further trials are in progress. 
 The Chinese Acute Stroke Trial (CAST) [20], and the 
concurrent International Stroke Trial (IST) [21], tested a 
policy of start aspirin immediately when a cerebral ischdmia 
is suspected; so aspirin should be started as soon as a CT or 
MR scan has been performed and has excluded intracranial 
haemorrhage as the cause of the stroke. Results of these two 
big trials shows clearly that starting daily aspirin promptly in 
patients with suspected acute ischemic stroke also reduces 
the immediate risk of further stroke or death in hospital and 
the overall risk of death or dependency, concluding that early 
aspirin is of benefit for a wide range of patients, and its 
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prompt use should be routinely considered for all patients 
with suspected acute ischemic stroke, mainly to reduce the 
risk of early recurrence. However, some uncertainly remains 
about the effects of early aspirin in particular categories of 
patient with acute stroke (eg, the elderly, those without a CT 
scan, or those with atrial fibrillation). 
 According to the European Stroke Organisation (ESO) 
Guidelines for Management of Ischaemic Stroke and Tran-
sient Ischaemic Attack [22] the use of low dose ASA in pri-
mary prevention is recommended in women aged 45 years or 
more who are not at increased risk for intracerebral haemor-
rhage and who have good gastrointestinal tolerance neverthe-
less cklincial studies have showed no dramatical preventive 
effect. It is also recommended that low-dose ASA may be 
considered in men for the primary prevention of MI; how-
ever, it does not reduce the risk of ischaemic stroke. ASA 
may be recommended for patients with non-valvular AF who 
are younger than 65 years and free of vascular risk factors. 
Unless contraindicated, either ASA or an oral anticoagulant 
(international normalized ratio, INR, 2.0–3.0) is recom-
mended for patients with non-valvular AF who are aged 65 – 
75 years and free of vascular risk factors. Low-dose ASA is 
recommended also for patients with asymptomatic ICA 
stenosis > 50% to reduce their risk of vascular events. Other 
antiplatelet drugs than ASA have not been studied in 
asymptomatic subjects and therefore cannot be 
recommended for primary stroke prevention. 
CLOPIDOGREL 
 Clopidogrel is a thienopyridine which has largely re-
placed ticlopidine because of its much better hematologic 
and cutaneous safety. Clopidogrel is an inactive prodrug that 
requires two-step oxidation by the hepatic cytochrome P450 
(CYP) system to generate its active compound, the thiol me-
tabolite, which targets and irreversibly inhibits the ADP P2Y 
purinoceptor 12 on circulating platelets. The hepatic CYP 
isoenzymes involved in this two-step metabolisation process 
of clopidogrel include CYP2C19, CYP3A4/5, CYP1A2, 
CYP2B6, and CYP2C9. 
 Several trial addressed the issue of the comparative effect 
between clopidogrel and aspirin in prevention of stroke. 
 In the CHARISMA Study [23] a prospective, multicen-
ter, randomized, double-blind, placebo-controlled study, 
15,603 patients were randomized to receive clopidogrel 75 
mg/day plus lowdose aspirin (75–162 mg/day) or placebo 
plus low-dose aspirin, with median follow-up of 28 months. 
All patients were 45 years of age or older and had either 
multiple atherothrombotic risk factors or a history of docu-
mented coronary disease, cerebrovascular disease, or symp-
tomatic PAD. The results showed no statistically significant 
difference between treatment groups in the rates of occur-
rence of the primary efficacy endpoint (clopidogrel plus as-
pirin 6.8%, aspirin alone 7.3%; RR 0.93, 95% CI 0.83–1.05; 
p = 0.22). Patients with multiple risk factors but no clearly 
established vascular disease (primary prevention cohort) did 
not benefit from the addition of clopidogrel to aspirin; in-
stead, adjunctive clopidogrel was associated with a non-
significant 20% relative increase in the rate of primary 
events, as well as an excess in cardiovascular mortality (3.9 
vs. 2.2%, p = 0.01). 
 A recent Cochrane review [24] found, evaluating 19.185 
high risk vascular patients, a significantl but strictly marginal 
improvement of long-term reduction of risk of stroke and 
other major vascular events by 8·7% (95% CI 0·3–16·5%) 
through use of clopidogrel in comparison to aspirin. Clopi-
dogrel also causes less gastrointestinal bleeding than 325 mg 
aspirin daily (RR 0·69 [95% CI 0·48–1·00]; absolute annual 
decrease 0·12% [0·00–0·28%]), but does not reduce the risk 
of other types of bleeding. However, the cost of clopidogrel 
is substantially greater than that of aspirin, and this might 
prevent its use, especially in less developed countries [24]. 
ANTIPLATELET DRUGS FOR SECONDARY PRE-
VENTION OF ISCHEMIC STROKE 
Approximately 25% of Strokes are Recurrent 
 Patients experiencing stroke or transient ischemic attack 
(TIA) are at high risk for recurrent (secondary) strokes, 
which comprise 29% of all strokes in the United States. Pro-
spective studies have shown that the early risk of stroke post 
TIA is much higher than previously thought —18% at 90 
days. More importantly, most of the recurrent strokes hap-
pened within the first 2 days after the index event [25, 26]. 
After 1 year the risk falls at about 5% per year [27]. 
 Current recommendations for prevention of secondary 
stroke from the American College of Chest Physicians 
(ACCP) [28] indicates for the broad use of antiplatelet ther-
apy for the prevention of recurrent stroke in patients with a 
history of non-cardioembolic stroke or TIA. Five agents-
aspirin, ticlopidine, clopidogrel, extended-release dipyrida-
mole (ER-DP), and triflusal--have demonstrated efficacy in 
large-scale clinical studies in the prevention of recurrent vas-
cular events and/or stroke in patients with a history of stroke. 
 Although clinicians may choose acetylsalicylic acid 
(ASA) as first-line therapy for secondary prevention, clinical 
guidelines and evidence from trials suggest that ASA may 
not be the most effective strategy [29].  
ASPIRIN 
 Aspirin represents an important therapeutic regimen to 
prevent the recurring of ischemic events or vascular death 
after an ischemic stroke.  
 The antiplatelet efficacy of aspirin in preventing secon-
dary stroke was established by three studies conducted in the 
late 1980s and early 1990s. The first of three was the Swed-
ish Aspirin Low-dose (SALT) Trial [30] that have demon-
strated that aspirin, even in doses as low as 30 mg/day, re-
duces secondary stroke, Myocardial infarction, or vascular 
death in patients with previous vascular event. At a dosage of 
75 mg/day in this trial aspirin reduced the rate of recurrent 
stroke by 18%.  
 Two subsequent studies, the Stroke Prevention in Re-
versible Ischemia Trial (SPIRIT) [31], an European trial that 
compared warfarin with aspirin in patients with TIA or mi-
nor stroke during the previous six months, and the Warfarin 
vs. Aspirin in Recurrent Stroke Prevention Study (WARSS) 
[32], in which lower doses of warfarin were hypothesize to 
guarantee a superior benefit to aspirin without the risk of 
untoward outcomes observed in the SPIRIT trial [31], 
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showed that aspirin was preferable to warfarin in preventing 
secondary stroke in patients with initial non-cardioembolic 
stroke. 
 Given the results of these studies, was clear that aspirin 
should be the therapeutic choice for secondary stroke pre-
vention unless a clear cardioembolic source, such as atrial 
fibrillation, is present.  
 The fact that low dose aspirin is of substantial benefit for 
people who already suffered of occlusive vascular disease 
was recently confirmed by ATT Collaboration Meta-analysis 
[19]: in the secondary prevention trials, aspirin allocation 
yielded a greater absolute reduction in serious vascular 
events (6.7% vs. 8.2% per year, p<0.0001), with a non-
significant increase in haemorrhagic stroke but reductions of 
about a fifth in total stroke (2.08% vs. 2.54% per year, 
p=0.002) and in coronary events (4.3% vs. 5.3% per year, 
p<0.0001). 
 Despite the fact that ASA remains the most popular, most 
commonly prescribed and widely accepted agent for secon-
dary stroke prevention in the world, its efficacy still does not 
exceed 25%. The development of the benchmark techniques 
for platelet-mediated haemostasis and platelet function moni-
toring in ASA users raise the possibility to triage low re-
sponse or so-called “ASA resistance”. The incidence of 
clinical aspirin resistance varies from 11% to 17.3% depend-
ing on the definition adopted [33], whereas the incidence of 
biochemical resistance ranges from as little as 5% to as much 
as 60% depending primarily on the platelet function assay 
used [34]. A high prevalence of ASA resistance (28.0–
65.0%) was also demonstrated among post-stroke ASA users 
[35]. None of the available platelet aggregation assays have 
convincingly been shown to correlate with recurrence of 
clinical events (ischemic stroke or MI) and the results be-
tween different assays have also been discordant. Because 
Aspirin resistance is a poorly defined phenomenon and it is 
likely to be multifactorial, and, to date, no standardized defi-
nition or test can be used to quantify either type of aspirin 
resistance as well as do not exist a therapeutic algorithm that 
helps clinical to evaluate how to treat an aspirin-resistant 
patient.  
 The association between increased platelet activity and 
high blood lipid content is not new. In an early small retro-
spective clinical study, hyperlipidemia has been found to 
enhance the risk of ASA failure in patients after first-ever 
ischemic stroke [36]. Indeed, the prevalence of hyperlipide-
mia in the ASA-resistant patients in that study was 65%, 
compared to 26% of the average ASA responders. A slight 
correlation between ASA resistance and conventional lipid 
biomarkers has been found in another study [37]. Patients 
with ASA resistance exhibited a higher total cholesterol/ 
HDL ratio and lipoproteins compared to ASA responders.  
 The assessment of the extent of adenosine diposphate 
(ADP)-induced platelet aggregation and its correlation with 
the outcome after an acute ischemic stroke in patients al-
ready taking aspirin therapy was the aim of a study by Cha et 
al. [38]. This study underlined individual differences in sub-
jects taking aspirin and assessed through different degree of 
ADP-induced platelet aggregation: increased ADP-induced 
aggregation is associated with a poor outcome after an acute 
ischemic stroke. This confirms, once more, a constitutional 
different degree of aspririn activity from a subject to another.  
TICLOPIDINE 
 Ticlopidine belongs to the group of thienopyridines, 
whose antiplatelet effect is based on the inhibition of 
adenosindiphosphate (ADP) and also on the blockage of the 
ADP mediated binding of fibrinogen membrane thrombocyte 
receptor, glycoprotein IIb/IIIa. 
 The Ticlopidine Aspirin Stroke Study (TASS) [39] found 
only slightly higher efficacy of ticlopidine 250 mg twice 
daily than ASA 1300 mg once daily in the secondary preven-
tion of stroke. However, when compared to ASA, the use of 
ticlopidine is associated with markedly more frequent side 
effects, such as diarrhea, gastro-intestinal intolerance, skin 
rash and haematological disorders but not with increased 
bleeding complications. Owing to these severe side effects 
ticlopidine is usually used as a second choice antiplatelet 
drug reserved for patients with ASA intolerance.  
CLOPIDOGREL AND THE COMBINATION ASPIRIN 
+ CLOPIDOGREL 
 Combined antiplatelet agents may offer additive protec-
tion over single drugs after stroke. Clopidogrel has been 
evaluated as monotherapy and in combination with aspirin 
with regard to its efficacy in preventing secondary stroke. 
 In the Clopidogrel vs. Aspirin in Patients at Risk of 
Ischemic Events (CAPRIE) study [40], three groups with a 
recent history of symptomatic cardiovascular disease (stroke, 
MI, or peripheral arterial disease) were randomized to clopi-
dogrel 75 mg/day or aspirin 325 mg/day to evaluate the 
composite outcome of ischemic stroke, MI, or vascular death 
as well as the relative safety of each drug. Clopidogrel was 
slightly more effective than aspirin in decreasing the com-
bined risk of ischemic stroke, myocardial infarction, and 
vascular death, in patients with symptomatic atherosclerotic 
vascular disease (8.7% Relative Risk Reduction; p = 0.043 in 
intention to treat and 9.4% in an on-treatment analysis). 
However, clopidogrel did not demonstrate superiority vs. 
aspirin in preventing recurrent stroke among patients with a 
history of stroke (8% RRR; p = 0.28), although the study 
was powered only to demonstrate significant differences in 
the overall population (n = 19,185). No major safety differ-
ences were observed between clopidogrel and aspirin, al-
though the rate of serious hemorrhage was slightly higher in 
the aspirin group (1.55 vs. 1.38%); cutaneous rashes and 
diarrhea were more frequent with clopidogrel [40]. 
 In the MATCH Trial [41] on the basis of previous trial 
results (including CAPRIE) in patients with cardiac and 
cerebrovascular disease, investigators sought to determine 
whether the addition of aspirin to clopidogrel would further 
reduce the risk of recurrent ischemic attacks in high-risk 
patients after recent ischemic stroke or TIA. Patients were 
included if they had a stroke or TIA within the previous 3 
months and 1 or more of 5 additional high-risk factors within 
the previous 3 years: previous stroke, previous MI, angina, 
diabetes, or symptomatic PAD. The results of MATCH 
showed no significant difference between clopidogrel alone 
and clopidogrel plus aspirin in reducing risk of vascular 
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events after stroke or TIA. Although there was an absolute 
risk reduction of 1% and a relative risk reduction of 6.4% 
favoring clopidogrel plus aspirin, the between-group differ-
ences were not statistically significant. Should be underlined, 
however, that there was a beneficial trend of the association 
antiplatelet therapy in the subgroup of patients randomly 
assigned to treatment within 7 days of a TIA or stroke. 
 Furthermore, in the CHARISMA Study Study [23], pre-
viously described in this review, analysis of data provided by 
patients with established cardiovascular disease (the secon-
dary prevention cohort), showed that the addition of clopi-
dogrel to aspirin therapy resulted in a marginally significant 
clinical benefit regarding the primary endpoint (6.9 vs. 7.9% 
with placebo; RR 0.88; 95% CI, 0.77–0.998; p = 0.046). Re-
sults of the safety analysis showed a non-significant increase 
in the primary safety endpoint of severe bleeding with clopi-
dogrel; the rate of moderate bleeding (that required transfu-
sion) was 2.1% in the clopidogrel group and 1.3% in the 
placebo group (RR, 1.62; 95% CI, 1.27–2.08; p<0.001). 
 Assessment of degree of platelet inhibition using one 
antiplatelet agent or the combination of two was the aim of a 
study involving 31 subjects with previous atherothrombotic 
or lacunar stroke. Patients were treated with aspirin (100 to 
300 mg/d), clopidogrel (75 mg/d) or both aspirin and clopi-
dogrel for 4 weeks [42]. Using as platelet-activation criterion 
collagene/ADP closure time authors demonstrated an higher 
degree of protection under combination therapy of aspirin + 
clopidogrel. Obviuosly, a lower risk of thrombisis is ever 
associated to a higher hemorrhagic risk.  
 Given the results showed, clopidogrel has been increas-
ingly used in secondary prevention after an ischemic stroke. 
Further data regarding the topic whether therapy with clopi-
dogrel + aspirin (C+ASA) will produce more evident platelet 
inhibition than aspirin alone (ASA) in patients after ischemic 
stroke were provided by Serebruany et al. in the PLUTO 
Trial [43]. In this study therapy with C+ASA resulted in a 
significant inhibition of platelet activity assessed by ADP- 
(P=0.00001) and collagen-induced (P=0.02) aggregation; 
closure time prolongation (P=0.03), and reduction of platelet 
activation units, indicating a greater inhibition of platelet 
activity of combination therapy than ASA alone in patients 
after an ischemic stroke.  
 The question of ultra-early secondary prevention, how-
ever, remains open, given the 1/3 relative risk reduction ob-
served in the Fast Assessment of Stroke and Transient 
Ischemic Attack to Prevent Early Recurrence (FASTER) 
study [44]. Patients with transient ischaemic attack (TIA) or 
minor stroke are at high immediate risk of stroke. The opti-
mum early treatment options for these patients are not still 
well assessed. Authors in this work ascertained that aggres-
sive and precocious secondary prevention operated adding 
clopidogrel to aspirin that was already used by all the sub-
jects enrolled, was able to provide a reduction of recurrence 
of ischemic events. The question of aggressive secondary 
prevention using combination therapy of antiplatelet drugs 
merits further studies. 
 On the basis of the current evidence for long-term treat-
ment of survivors of ischemic stroke or TIA, clopidogrel is 
an effective alternative for patients who are intolerant to as-
pirin [44-46]. 
 Likewise aspirin, a so called clopidogrel-reistance has 
been identificated in the latest years, to individuate the cause 
of the occurrence in a variable amount of patients treated 
with a dequate dosage of clopidogrel of ischemic of ischemic 
events.  
 The prevalence of clopidogrel non-response in different 
populations has been described as between 4% and 30%. 
There are several potential mechanisms of clopidogrel resis-
tance, which can be divided into two main groups, both in-
volving CYP metabolism: 1) extrinsic mechanisms (i.e. drug 
interactions involving CYP3A4) and 2) intrinsic mechanisms 
(i.e. polymorphisms of P2Y12 receptor and CYP3As). In 
regard to drug interactions, any medication that interacts 
with (either inhibiting or increasing) CYP3A4 can poten-
tially block the conversion of clopidogrel into its active me-
tabolite. Among these drugs, statins, except for pravastatin, 
might interfere with clopidogrel metabolism. The antiplatelet 
activity has also been shown to be reduced in about a third of 
patients receiving omeprazole, protonpump Inhibitor which 
is a CYP2C19 inhibitor [47]. However, other authors have 
critically evaluated this observation [48]. 
 Recently, several reports indicate that certain polymor-
phisms in the hepatic cytochrome p450 system are associated 
with an excess of vascular events. Patients who are carriers 
of a loss of function of CYP2C19 allele (including the *2 
and *3 alleles) might have a reduced rate in the conversion to 
an active metabolite, therefore resulting in a decreased inhi-
bition of platelets. Carriers of less functional alleles com-
pared with non-carriers showed a significant increase in the 
risk of major vascular events [49, 50]. A recent analysis of 
data among 5,059 patients with acute coronary syndromes or 
atrial fibrillation showed that the response to clopidogrel 
compared with placebo was consistent, irrespective of 
CYP2C19 loss-of-function carrier status [51]. Therefore, it is 
possible that loss-of-function variants do not directly alter 
the efficacy and safety of clopidogrel. Consequently, clopi-
dogrel should be used regardless of the carrier status until 
further studies can elucidate this paradox. 
DIPYRIDAMOLE AND THE COMBINATION ASPI-
RIN + DIPYRIDAMOLE 
 Dipyridamole is a weak antiplatelet drug that has been 
combined with aspirin for over 30 years in the secondary 
prevention of non-cardioembolic ischemic stroke. By con-
trast with four early studies, which showed no benefit of the 
combination over aspirin alone using immediate-release 
dipyridamole formulation, more recent studies using ex-
tended-release dipyridamole and higher doses (400 mg), 
such as the European Stroke Prevention Study 2 (ESPS2) 
[52], one of two studies that evaluated aspirin plus extended-
release dipyridamole for secondary stroke prevention, 
showed a significant benefit of the combination over aspirin 
alone (50 mg). In ESPS-2, 6,602 patients who had a recent 
ischemic stroke or TIA were enrolled in a multicenter, dou-
ble-blind, placebo-controlled trial that randomly assigned 
them to one of four treatment groups: aspirin (25 mg, twice 
daily), extended-release dipyridamole (200 mg, twice daily), 
aspirin plus extended-release dipyridamole, or placebo. Both 
agents given as monotherapy demonstrated an independent 
and statistically significant reduction in recurrent stroke 
(18% [P = 0.013], and 16%, [P = 0.039], respectively). How-
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ever, the combination of aspirin plus extended-release 
dipyridamole reduced stroke recurrence by 23.1 % (P = 
0.006) compared with aspirin alone and by 37% (P < 0.001), 
compared with placebo. Results from ESPS-2 indicate that 
aspirin plus extended-release dipyridamole has significant 
benefit over aspirin alone for prevention of second 
stroke.The benefit of the combination was obtained without a 
significant increase in hemorrhagic events. 
 The European/Australasian Stroke Prevention in Re-
versible Ischaemia (ESPRIT) Study Group [53] included a 
meta-analysis of six comparative trials, including a total of 
3,888 patients taking aspirin plus dipyridamole and 3,907 
taking aspirin alone; this analysis demonstrated an overall 
RRR for combination therapy vs. aspirin of 18% (95% CI, 
0.74–0.91) for the composite outcome of vascular death, 
non-fatal stroke, or non-fatal MI. ESPRIT investigators 
found that combination treatment was not associated with a 
higher complication rate than ASA monotherapy, but that the 
rate of withdrawal due to adverse events was higher in the 
group that received the combination. 
 The Prevention Regimen for Effectively avoiding Second 
Strokes (PROFESS) trial [54] was initially designed to com-
pare 2 combinations: aspirin + dipyridamole and aspirin + 
clopidogrel, but aspirin was stopped in the aspirin 
+clopidogrel arm after the results of the MATCH trial [41] 
when 1,920 patients had been included. PROFESS is thus 
mostly a comparison of the combination aspirin + ER 
dipyridamole (25 mg + 200 mg twice daily) and clopidogrel 
(75 mg daily) alone. It included 20,332 high-risk patients 
with a mean age of 66.1 years, less than 90–120 days after a 
TIA or ischemic stroke. After a median follow-up of 2.4 
years, recurrent stroke occurred in 9% of patients in both 
groups (9.0% on aspirin plus ER dipyridamole vs. 8.8% on 
clopidogrel; HR 1·01 [95% CI 0·92–1·11]), and the compos-
ite outcome of stroke, myocardial infarction and death from 
vascular causes occurred in 13.1 % of patients in both 
groups. Thus, the combination of aspirin + ER dipyridamole 
is not better than clopidogrel alone in preventing stroke re-
currence. 
 Patients with transient ischaemic attacks (TIA) and minor 
ischaemic strokes are at risk of serious vascular events (death 
from all vascular causes, non-fatal stroke, or non-fatal myo-
cardial infarction). Their risk of vascular events lies between 
4 and 11 percent per year. The combination of aspirin and 
ER dipyridamole is significantly more effective than aspirin 
alone in reducing the risk of stroke and other major vascular 
events (hazard ratio [HR] 0·82 [95% CI 0·72–0·92]), without 
excessive bleeding or myocardial infarction in patients with 
previous TIA or ischaemic stroke. Aspirin only, in a daily 
dose of 30 mg or more, offers only modest protection in such 
patients: it reduces the incidence of major vascular events by 
13 percent. Adding ER dipyridamole to aspirin was associ-
ated with a 22 percent reduction in the risk of major vascular 
events compared with aspirin alone [55]. 
CONCLUSIONS 
 Although the certain clinical value of antiplatelet therapy, 
and especially of aspirin, is well recognized, several ques-
tions about antiplatelet therapy in subject with ischemic 
stroke remain open and need to be further clarified; first: 
effectiveness of combination therapy with anticoagulants. 
Anticoagulant therapy in ischemic stroke is the matter of 
another review in this journal, but in the 2002 a Cochrane 
review [56] and a recent critical review [57] showed that 
combining antiplatelet and anticoagulant therapy appears to 
be more effective than antiplatelet therapy alone for the ini-
tial and longterm management of ACS, and is more effective 
than anticoagulants alone in patients with mechanical heart 
valves, but increases the risk of bleeding. There is no evi-
dence from RCTs that combination therapy compared with 
antiplatelet therapy alone is more effective for the prevention 
of recurrent cardiovascular events in patients with non-
cardioembolic stroke or peripheral artery disease, or com-
pared with anticoagulant therapy alone for the prevention of 
stroke in patients with atrial fibrillation. Combination ther-
apy is commonly used in patients with separate indications 
for antiplatelet therapy (e.g. acute coronary syndrome, recent 
coronary artery stent) and anticoagulant therapy (e.g. atrial 
fibrillation with at least one additional risk factor for stroke) 
despite lack of evidence from randomized controlled trials. 
 Second: timing of antiplatelet administration. Third: 
choose of antiplatelet drug and effecfiveness of combination 
therapy in different clinical settings. This matter has been yet 
investigated in several trial, analyzed previously in this re-
view; summarizing the available evidences, the indirect 
comparisons of different agents seems not to show any evi-
dence of significant heterogeneity of effect between the dif-
ferent agents tested: aspirin alone, ticlopidine alone, the 
combination of aspirin and dipyridamole, thromboxane syn-
thase inhibitor, and the GP IIb/IIIa inhibitor abciximab. In 
comparative monotherapy studies of patients with previous 
stroke, ticlopidine seems to demonstrate slight statistically 
significant improved efficacy over aspirin, and clopidogrel 
demonstrates non-significant slight improvement over aspi-
rin for the prevention of ischemic cardiac and cerebrovascu-
lar events; however, the adverse event profile of ticlopidine 
(including rash, diarrhea, and neutropenia) will probably 
limit its long-term use. Among combination approaches, 
only aspirin plus ER-DP has demonstrated statistically sig-
nificant, clinically meaningful additive benefit over mono-
therapy with each agent. 
 Fourth: optimal dosage of antiplatelet drugs. The benefits 
of aspirin in acute stroke are drawn from trials which tested a 
dose of aspirin between 160 mg and 330 mg daily. In acute 
myocardial infarction, 160 mg is the lowest dose that has 
been shown to be effective [19]. Lower doses of aspirin are 
effective for long-term secondary stroke prevention, but have 
not been evaluated in acute stroke. There is some (but not 
abundant) evidence that at least 120 mg of aspirin is needed 
to acetylate all circulating platelets within a short period of 
time [20]. Fifth: way of administration. For patients who can 
swallow, aspirin can be given by mouth. However, as many 
people with stroke are unable to swallow, another route may 
need to be used on occasions. In the CAST trial [20], aspirin 
was given via a nasogastric tube, and in the IST [21], as a 
rectal suppository, or intravenously as 100 mg of the lysine 
salt of acetylsalicylic acid.  
 Sixth: do the future provide new antiplatelet compunds, 
actually under development, able to offer addictional benefit 
without increase the risk of bleedings? 
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 Other interesting topics regards, for example, the possi-
bility of different degree of activity of antiplatelet drugs 
when used in combination with other class of drugs such as 
antihypertensives, namely angiotensin-II blocker agents and 
statins. About this, Yu et al. recently reported a more favor-
able functional outcome ten days after an acute stroke in 
subjects taking the combination of these three classes of 
therapies [58]. Furthermore, a putative neuroprotective ac-
tion of antiplatelet compounds and of other class of drugs 
such as angiotensin receptor blockers (ARBs) was hypothe-
sized. In the PRoFESS Trial the combination aspirin + 
dypidiridamole, the thyenopiridine clopidogrel and the ARB 
telmisartan were tested, among the other oucomes, also for 
the assessment of this effect. Unfortunately, there was no 
significant difference in the proportion of patients with re-
current stroke with a good outcome, as measured with the 
Barthel index, across all treatment groups. Additionally, 
there was no significant difference in the median mini-
mental state examination (MMSE) scores, and the number of 
patients with dementia among the treatment groups. Disabil-
ity due to recurrent stroke and cognitive decline in patients 
with ischaemic stroke were not different between the two 
antiplatelet regimens and were not affected by the preventive 
use of telmisartan. 
 As underlined before, antiplatelet medications are the 
agents of choice for secondary prevention of non-cardioem- 
bolic ischemic strokes. In patients who are at high risk be-
cause they already have occlusive vascular disease, long-
term antiplatelet therapy (e.g. with aspirin) reduces the 
yearly risk of serious vascular events (non-fatal myocardial 
infarction, non-fatal stroke, or vascular death) by about a 
quarter. Multiple clinical trials have proven their reliable 
albeit modest clinical benefits and relatively good safety 
profile. This decrease typically corresponds to an absolute 
reduction of about 10–20 per 1000 in the yearly incidence of 
non-fatal events, and to a smaller, but still definite, reduction 
in vascular death. Against this benefit, the absolute increase 
in major gastrointestinal or other major extracranial bleeds is 
an order of magnitude smaller. Hence, for secondary preven-
tion, the benefits of antiplatelet therapy substantially exceed 
the risks. 
 For primary prevention, however, the balance is less clear 
because the risks without aspirin, and hence the absolute 
benefi ts of aspirin, are generally an order of magnitude 
lower than in secondary prevention. Previous meta-analyses 
of primary prevention trials were not based on individual 
participant data, so they could not compare reliably the bene-
fits and risks of aspirin in prognostically important groups 
(such as older people and others at increased risk of coronary 
heart disease), and could not quantify reliably the extent to 
which people at increased risk of coronary heart disease 
might also be at increased risk of bleeding. 
 The most commonly recommended antiplatelet agents for 
secondary stroke prevention in North America and Europe 
are aspirin, clopidogrel, and the combination of aspirin and 
extended-release dipyridamole. Because of the multiple 
pharmacologic mechanisms available for platelet inhibition, 
combination antiplatelet agents have the potential for syner-
gistic effects. However, combinations of antithrombotic 
agents do not necessarily improve clinical efficacy and are 
typically associated with increased toxicity. Clopidogrel and 
aspirin have been used in combination in patients with di-
verse arterial vascular diseases. Combination antiplatelet 
therapy with clopidogrel and aspirin has established clinical 
benefits, particularly in coronary disease and in patients who 
have undergone coronary stenting. Although it is tempting to 
extrapolate the benefits of clopidogrel and aspirin to the set-
ting of secondary stroke prevention, recent clinical trials 
have failed to document significant clinical benefits in cere-
brovascular patients. This failure has occurred because of a 
lack of significant efficacy for prevention of vascular events 
and a substantial increase in bleeding risk. Therefore, the 
clopidogrel and aspirin combination is not recommended for 
recurrent stroke prevention. In general, when clopidogrel is 
used for cerebrovascular patients, the addition of aspirin 
should be avoided unless there is a specific cardiac indica-
tion such as recent acute coronary syndrome or a coronary 
stent. 
 The use of the combination therapy of aspirin + ER-DP is 
supported by Class I data from two large studies demonstrat-
ing superiority over aspirin alone for recurrent stroke preven-
tion. Although dual antiplatelet therapy with clopidogrel and 
aspirin has never been directly compared with the combina-
tion of aspirin and extended-release dipyridamole, clinical 
trial results favor the latter for secondary stroke prevention. 
Currently, there are no data for primary stroke prevention 
with dual antiplatelet agents regarding aspirin and extended-
release dipyridamole. Limited data from the recent Clopi-
dogrel for High Atherothrombotic Risk and Ischemic Stabili-
zation Management and Avoidance (CHARISMA) Study 
[23] trial indicate that the combination of clopidogrel and 
aspirin may be harmful, compared with aspirin alone. 
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